Gil Roth01.08.14
Phase I
Rexahn begins solid tumor trial . . . read more
Phase III
Catalyst, BioMarin post positive Firdapse results . . . read more
Repros' Androxal in head-to-head testosterone trial . . . read more
Phase IV
Exparel performs strongly against IV PCA opioid . . . read more
Filings
EMA accepts HCV MAA from BMS . . . read more
NPS BLA accepted for hypoparathyroidism . . . read more
Approvals
Merck HIV treatment approved in oral suspension . . . read more
Rexahn begins solid tumor trial . . . read more
Phase III
Catalyst, BioMarin post positive Firdapse results . . . read more
Repros' Androxal in head-to-head testosterone trial . . . read more
Phase IV
Exparel performs strongly against IV PCA opioid . . . read more
Filings
EMA accepts HCV MAA from BMS . . . read more
NPS BLA accepted for hypoparathyroidism . . . read more
Approvals
Merck HIV treatment approved in oral suspension . . . read more